humanize

Alemtuzumab, a humanized anti-CD52 antibody, has shown promise in tolerogenic induction protocols, requiring minimal maintenance immunosuppression.

阿仑单,一种人源-CD52体,在免疫耐受诱导方案中效果显著,需要最少的免疫抑制维持药物.

Therapeutic mAbs has developed from reshaping antibody and humanized antibody to fully human antibody in order to lower supersensitivity resulting from mouse antibody.

为了降低鼠源体引起的超敏反应,治疗单克隆体已由改型体,人源化体发展到全人体。